EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Specificity Proteins (Sp) and Cancer

Stephen Safe iD

International Journal of Molecular Sciences · 08.03.2023 · 24 (6) · 5164

DOI: 10.3390/ijms24065164 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.03.2023. Verfasst von Stephen Safe. Beteiligte Einrichtung: Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, MicroRNAs, Rhabdomyosarcoma. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The specificity protein (Sp) transcription factors (TFs) Sp1, Sp2, Sp3 and Sp4 exhibit structural and functional similarities in cancer cells and extensive studies of Sp1 show that it is a negative prognostic factor for patients with multiple tumor types. In this review, the role of Sp1, Sp3 and Sp4 in the development of cancer and their regulation of pro-oncogenic factors and pathways is reviewed. In addition, interactions with non-coding RNAs and the development of agents that target Sp transcription factors are also discussed. Studies on normal cell transformation into cancer cell lines show that this transformation process is accompanied by increased levels of Sp1 in most cell models, and in the transformation of muscle cells into rhabdomyosarcoma, both Sp1 and Sp3, but not Sp4, are increased. The pro-oncogenic functions of Sp1, Sp3 and Sp4 in cancer cell lines were studied in knockdown studies where silencing of each individual Sp TF decreased cancer growth, invasion and induced apoptosis. Silencing of an individual Sp TF was not compensated for by the other two and it was concluded that Sp1, Sp3 and Sp4 are examples of non-oncogene addicted genes. This conclusion was strengthened by the results of Sp TF interactions with non-coding microRNAs and long non-coding RNAs where Sp1 contributed to pro-oncogenic functions of Sp/non-coding RNAs. There are now many examples of anticancer agents and pharmaceuticals that induce downregulation/degradation of Sp1, Sp3 and Sp4, yet clinical applications of drugs specifically targeting Sp TFs are not being used. The application of agents targeting Sp TFs in combination therapies should be considered for their potential to enhance treatment efficacy and decrease toxic side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMicroRNAsRhabdomyosarcomaHumansSp Transcription FactorsSp1 Transcription FactorSp3 Transcription FactorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Sp1Sp3Sp4non-oncogene addictionpro-oncogenicprognostic

Substanzen

Sp Transcription FactorsAntineoplastic AgentsMicroRNAsSp1 Transcription FactorSp3 Transcription Factor

Autor:innen und Institutionen

  • Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.

ORCID-Profile: Stephen Safe

Förderung

  • NIEHS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Safe, S. (2023). Specificity Proteins (Sp) and Cancer. International Journal of Molecular Sciences, 24(6), 5164. https://doi.org/10.3390/ijms24065164

Vancouver

Safe S. Specificity Proteins (Sp) and Cancer. International Journal of Molecular Sciences. 2023;24(6):5164. doi:10.3390/ijms24065164

BibTeX
@article{Safe2023,
  author = {Safe, Stephen},
  title = {Specificity Proteins (Sp) and Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5164},
  doi = {10.3390/ijms24065164}
}
Kostenlos starten →